The review concluded that vancomycin was as effective as other antibiotics for patients with gram-positive infections such as pneumonia, bacteraemia, febrile neutropenia and skin and (only for high quality studies) soft-tissue infections. Despite poor reporting the review appeared generally well conducted but the reliability of the overall conclusions is unclear as results varied for individual antibiotic comparisons.
Study selection
Randomised controlled trials (RCTs) that compared vancomycin versus another antibiotic for gram-positive infections were eligible for inclusion. Studies needed to assess effectiveness, toxicity or mortality. Trials with masked or unmasked design were included. Experimental studies, studies of pharmacokinetic or pharmacodynamic variables and trials of older antibiotics or beta-lactams were excluded. Hospital admission of patients was not required. Infections were defined using the individual trial definitions. Complicated and uncomplicated skin and soft-tissue infections were included in the meta-analysis. One trial with low treatment duration was excluded. Primary outcomes were treatment success (cure or improvement) in intention-to-treat (ITT) and clinically evaluable populations, all-cause mortality in the ITT population and adverse events. Secondary outcomes were treatment duration (ITT population) and microbiological assessment.
Vancomycin was compared to teicoplanin (20 trials), linezolid (14 trials), telavancin (four trials) and daptomycin, tigecycline, ceftaroline, ceftobiprole, quinupristin-dalfopristin, dalbavancin and iclaprim in fewer trials. Most studies allowed other concomitant antibiotics. Most studies were of adult patients and three were of children; 22 were of hospitalised patients. Most studies concentrated on one type of infection.
Two independent reviewers performed the study selection.
Assessment of study quality
Study quality was assessed using a modified Jadad scale with five criteria for randomisation, generation of randomised numbers, double-blinding, withdrawals and allocation concealment. The maximum score possible was 5. High quality studies had a score of at least 3 and low quality studies scored 2 or less.
The authors implied that quality data was extracted in the same way as other data.
Data extraction
Data were extracted for the ITT, clinically evaluable and microbiologically evaluable populations. Numbers of patients and events in each group were used to calculate odds ratios (OR) with 95% confidence intervals (CIs).
Two independent reviewers performed the data extraction. Disagreements resolved by discussion among all four reviewers.
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Results were pooled to give odds ratios with 95% CIs using a fixed-effect model (Mantel-Haenszel) where there was no significant heterogeneity and a random-effects model (DerSimonian and Laird) where there was significant heterogeneity. Between-study heterogeneity was determined using the Χ² test (p< 0.1 considered significant) and Ι² statistic (>40% considered substantial). Publication bias was assessed using Egger's test and visually using funnel plots. Subgroup analyses were performed by type of comparator antibiotic, by infection type (pneumonia, bacteraemia or skin and soft-tissue infections) and for double-blind and open-label trials.
Results of the review
Fifty-three RCTs were identified (17,420 participants, range 21 to 1,897). The mean quality score was 2.7 (median 2, range 1 to 5); 26 trials had a high quality score and there were 21 double-blind trials.
Effectiveness (treatment success or cure): Overall there was no significant difference in effectiveness between comparator antibiotics and vancomycin (OR 1.08, 95% CI 0.98 to 1.18; Ι²=0%; 41 comparisons) with no significant differences between vancomycin and individual antibiotics. Comparators were as effective as vancomycin for the ITT population and the microbiologically evaluable population but significantly more effective versus vancomycin for the clinically evaluable population (OR 1.14, 95% CI 1.02 to 1.27; Ι²=12%; 49 comparisons); this result was also significant for single-blind and open-label studies but not for double-blind studies. There were no significant differences in effectiveness overall for febrile neutropenia, pneumonia or skin and soft-tissue infections but linezolid was significantly more effective than vancomycin for skin and soft-tissue infections (OR 1.61, 95% CI 1.07 to 2.43).
Mortality: There was no significant difference in mortality for comparators versus vancomycin (OR 1.09, 95% CI 0.96 to 1.23; Ι²=0%; 41 comparisons) and no significant differences between vancomycin and individual antibiotics. There was no significant difference for the overall ITT population. Mortality was higher for the comparator antibiotics in single-blind and open-label studies but not for double-blind studies. This significant result was dominated by one openlabel study of patients with both gram-negative and gram-positive infections that compared linezolid with vancomycin; the result was no longer significant when it was omitted from the meta-analysis.
Adverse events: There were overall no significant differences in adverse events (OR 1.07, 95% CI 0.90 to 1.28), withdrawals or episodes of recurrent infections for comparators versus vancomycin and no significant differences for the subgroup analyses for double-blind and for single-blind and open-label studies. Results for individual antibiotic comparisons with vancomycin varied in significance.
Authors' conclusions
On the basis mainly of data from open-label trials, vancomycin was as effective as other available antibiotics for patients with gram-positive infections including pneumonia, bacteraemia and febrile neutropenia. Open-label trials of patients with skin and soft-tissue infections showed vancomycin was less effective than linezolid but had a lower mortality rate but this was not evident for double-blind trials or for patients with severe infections. Study design seemed to make a major contribution to the outcome.
